SADBE in pediatric alopecia areata

Phase 1, randomised trial in alopecia areata comparing Placebo -> SADBE with SADBE (2 arms). Primary endpoints: Hair loss as assessed by number of subjects that score <30 on the Severity of Alopecia Tool (SALT) at 12 months, Hair loss as assessed by the number of subjects that score <50 on the Severity of Alopecia Tool (SALT) at 4 months and 5 more. Status: unknown.